Overview
GH Research is a clinical-stage biopharmaceutical company developing inhaled 5-MeO-DMT (GH001) as a rapid-acting treatment for treatment-resistant depression. Their proprietary inhalation delivery method is designed to produce predictable, short-duration psychedelic experiences.
More in Mental Health Tech
Latest industry news
FDA Grants De Novo Approval to Modius Spero, Clearing First Neuromodulation Device for PTSD
2026-09-03 · Policy
Butterfly Network's BCI Chip Licensing Deal Rattles Investors as Shares Drop Nearly 10%
2026-09-02 · Industry
Merge Labs and Butterfly Network Unite to Push Ultrasound-Based BCIs Into the Mainstream
2026-09-01 · Industry
FDA Grants CorTec Second Breakthrough Device Designation for Its Brain-Computer Interface
2026-08-31 · Policy
Company details
Category
💙 Mental Health Tech
Location
Dublin, Ireland
Funding
Public · NASDAQ: GHRS
Website
gh.bioListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →